Abstract: The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.

Abstract: Methods and apparatus for end-to-end data plane offloading for distributed storage using protocol hardware and Protocol Independent Switch Architecture (PISA) devices. Hardware-based data plane forwarding is implemented in compute and storage switches that comprise smart server switches running software executing in a kernel and user space. The compute switch is coupled to one or more compute servers/nodes and the storage server is coupled to one or more storage servers or storage arrays. The hardware-based data plane forwarding facilitates an end-to-end data plane between the computer server(s) and storage server(s)/array(s) that is offloaded to hardware. In one example the software comprises Ceph components used to implement control plane operations in connection with hardware offloaded data plane operations, and storage traffic employs the NVMe-oF protocol and the kernels include NVMe-oF modules. In one aspect the hardware-based data plane forwarding is implemented using programmable P4switch chips.

Abstract: A composition, comprising: two or more oligosaccharides selected from the group consisting of 2?-fucosyllactose (2?FL), 3-fucosyllactose (3FL), and 3?-sialyllactose (3?SL) is disclosed.

Abstract: In one example, a processor includes: at least one core to execute instructions; and at least one cache memory coupled to the at least one core, the at least one cache memory to store data, at least some of the data a copy of data stored in a memory. The at least one core is to determine whether to conditionally offload a sequence of instructions for execution on a compute circuit associated with the memory, based at least in part on whether one or more first data is present in the at least one cache memory, the one or more first data for use during execution of the sequence of instructions. Other embodiments are described and claimed.

Abstract: In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject. In some embodiments, the method comprises administering a combination therapy comprising an anti-HER2 antibody and tucatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent (e.g., an antimetabolite) to the subject. Pharmaceutical compositions and kits are also provided herein.

Abstract: Disclosed examples implement inter-process communication using a shared memory with a shared heap. Disclosed examples send a request from a first process to a second process, the request to cause allocation of a shared heap in shared memory; determine a first virtual address range of the first process for the shared heap in the shared memory based on the first virtual address range matching a second virtual address range from the second process in the shared memory; and write information from the first process to the shared heap, the information to be accessed by the second process from the shared heap.

Abstract: Devices, systems, and methods of using ammunition cartridge blocks to hold a plurality of cartridges upright, including a first layer having a plurality of openings configured to receive the plurality of ammunition cartridges, a second layer having a plurality of holes alignable with the plurality of openings and configured to receive the plurality of ammunition cartridges, the second layer positioned above the first layer, and a third layer having a plurality of holes aligned with the plurality of openings and configured to receive the plurality of ammunition cartridges, the third layer positioned above the second layer, the second layer adjustable with respect the first layer. An operator may adjust the second layer to lock the plurality of cartridges into position.

Abstract: The disclosure provides methods of treating solid tumors with a combination of tucatinib, or salt or solvent thereof, and an anti-PD-1 antibody, or an antigen-binding fragment thereof. The disclosure also provides methods of treating solid tumors with a combination of tucatinib, or salt or solvent thereof, and an anti-PD-L1 antibody, or an antigen-binding fragment thereof.

Abstract: Wheelbarrow accessories are presented including: a base for mechanically coupling with a pair of wheelbarrow arms; and an extendable arm assembly mechanically coupled with the base where the extendable arm assembly is vertically adjustable, the extendable arm assembly including; an outer arm pivotally engaged with the base; an inner arm slidingly engaged with the outer arm along an inner surface of the outer arm, where the inner arm is adjustable to a number of extendable arm lengths; a pad base coupled with the inner arm along a distal end of the inner arm; and a pad coupled with the pad base.

Abstract: In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject. In some embodiments, the method comprises administering a combination therapy comprising an anti-HER2 antibody and tucatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent (e.g., an antimetabolite) to the subject. Pharmaceutical compositions and kits are also provided herein.

Abstract: This invention relates to compounds that inhibit or modulate the activity of Chk-1 kinase. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.

Abstract: Some embodiments provide a network forwarding IC with packet processing pipelines, at least one of which includes a parser, a set of match-action stages, and a deparser. The parser is configured to receive a packet and generate a PHV including a first number of data containers storing data for the packet. A first match-action stage is configured to receive the PHV from the parser and expand the PHV to a second, larger number of data containers storing data for the packet. Each of a set of intermediate match-action stage is configured to receive the expanded PHV from a previous stage and provide the expanded PHV to a subsequent stage. A final match-action stage is configured to receive the expanded PHV and reduce the PHV to the first number of data containers. The deparser is configured to receive the reduced PHV from the final match-action stage and reconstruct the packet.

Abstract: The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.

Abstract: Some embodiments provide a network forwarding IC with packet processing pipelines, at least one of which includes a parser, a set of match-action stages, and a deparser. The parser is configured to receive a packet and generate a PHV including a first number of data containers storing data for the packet. A first match-action stage is configured to receive the PHV from the parser and expand the PHV to a second, larger number of data containers storing data for the packet. Each of a set of intermediate match-action stage is configured to receive the expanded PHV from a previous stage and provide the expanded PHV to a subsequent stage. A final match-action stage is configured to receive the expanded PHV and reduce the PHV to the first number of data containers. The deparser is configured to receive the reduced PHV from the final match-action stage and reconstruct the packet.

Abstract: In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject. In some embodiments, the method comprises administering a combination therapy comprising an anti-HER2 antibody and tucatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent (e.g., an antimetabolite) to the subject. Pharmaceutical compositions and kits are also provided herein.

Abstract: The invention provides methods of treating cancer, such as cancers with a HER2 mutation, with tucatinib, or salt or solvate thereof. The invention also provides compositions and kits comprising tucatinib for use in treating cancer, such as cancers with a HER2 mutation.

Abstract: Isolated antibodies or antigen-binding portions that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody or antigen-binding portion thereof has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT.

Abstract: An interfragmentary guide and plate system is described.

Abstract: This disclosure provides anti-apolipoprotein L1 (APOL1) antibodies, including anti-APOL1 antibodies that distinguish the GO and G1 forms from the G2 form of APOL1, distinguish APOL1 found on podocytes from that found on HDL particles in serum, and distinguish APOL1 from apolipoproteins L2, L3, L4 and L6 (APOL2, APOL3, APOL4 and APOL6), and methods of using the same.

Abstract: Isolated antibodies that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT. In some embodiments, the antibodies are afucosylated.